儿科药学杂志2024，Vol.30Issue(8)：12-16,5.DOI:10.13407/j.cnki.jpp.1672-108X.2024.08.003
贝林妥欧单抗治疗儿童急性淋巴细胞白血病的安全性分析及药学监护
Safety Analysis and Pharmaceutical Care of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia in Children
摘要
Abstract
Objective:To investigate the adverse drug reactions and management measures of blinatumomab in the treatment of acute lymphoblastic leukemia(ALL)in children,in order to provide reference for pharmaceutical care.Methods:PubMed,EMBase,CNKI,Wanfang and Sinomed databases were retrieved to collect the relevant literature.Clinical trial data were retrieved from ClinicalTrials.gov,and pharmacovigilance data were retrieved from U.S.Food and Drug Administration Adverse Event Reporting System(FAERS).The types,incidence and treatment measures of adverse drug reactions that may occur in the treatment of ALL with belintuozumab were reviewed.Results:Compared with traditional chemotherapy regimens,the incidence of total adverse drug reactions of belintuozumab was lower and the overall safety was better.The most significant adverse drug reactions included cytokine release syndrome,immune effector cell-related neurotoxic syndrome,hypogammaglobulinemia,decreased blood count and infection.Based on pharmacological properties,early prevention,recognition,rapid symptomatic management and patient education were the focus of pharmaceutical care.Conclusion:The safety of belintuozumab in the treatment of children with ALL is good,early detection and symptomatic management of pharmaceutical care are crucial to reduce adverse drug reactions.关键词
贝林妥欧单抗/儿童/急性淋巴细胞白血病/不良反应/药学监护Key words
blinatumomab/children/acute lymphoblastic leukemia/adverse drug reactions/pharmaceutical care分类
医药卫生引用本文复制引用
李雁铭,孙熙木,漆佩静,李英,丁倩,张瑞东,王晓玲..贝林妥欧单抗治疗儿童急性淋巴细胞白血病的安全性分析及药学监护[J].儿科药学杂志,2024,30(8):12-16,5.基金项目
北京药学会临床药学项目,编号LCYX-2022-08. （）
